GALDERMA LAUNCHES "SCRATCH RESISTANCE" CAMPAIGN TO VALIDATE THE PHYSICAL AND EMOTIONAL BURDENS OF ATOPIC DERMATITIS

GALDERMA LAUNCHES "SCRATCH RESISTANCE" CAMPAIGN TO VALIDATE THE PHYSICAL AND EMOTIONAL BURDENS OF ATOPIC DERMATITIS

National TV and digital media campaign aims to motivate patients to seek treatment for relentless itch with NEMLUVIO® (nemolizumab-ilto)NEMLUVIO® (nemolizumab-ilto) is the first and only approved neuroimmune targeted treatment that directly targets IL-31, a key driver of itch, inflammation and…

Galderma Launches ‘Scratch Resistance’ Campaign for Atopic Dermatitis Treatment

The broadcast and digital campaign aims to spotlight the emotional burden of eczema-related itch and promote Galderma’s Nemluvio. Galderma announced the launch of “Scratch Resistance,” its new broadcast advertisement and first multichannel campaign for Nemluvio, a treatment for atopic dermatitis, that spotlights the burden of atopic dermatitis beyond the itch.  “Itch is the most common symptom of atopic dermatitis, but the impact of itch is ofte…

GALDERMA LAUNCHES "SCRATCH RESISTANCE" CAMPAIGN TO VALIDATE THE PHYSICAL AND EMOTIONAL BURDENS OF ATOPIC DERMATITIS - PressReach

National TV and digital media campaign aims to motivate patients to seek treatment for relentless itch with NEMLUVIO® (nemolizumab-ilto) NEMLUVIO® (nemolizumab-ilto) is the first and only approved neuroimmune targeted treatment that directly targets IL-31, a key driver of itch, inflammation and skin barrier (epidermal) dysfunction in patients with atopic dermatitis (eczema) BOSTON, April 22, 2025 /PRNewswire/ — Galderma (SIX: GALD), the pure-pla…